Evidence map›Paper›PMID 39317567›Full record

ArticleJournal of pediatric surgery2025

Evaluation of Image-Defined Risk Factor (IDRF) Assessment in Patients With Intermediate-risk Neuroblastoma: A Report From the Children's Oncology Group Study ANBL0531.

Erin G Brown, E Stanton Adkins, Peter Mattei, Fredric A Hoffer, Sandra L Wootton-Gorges, Wendy B London, Arlene Naranjo, Mary L Schmidt, Michael D Hogarty, Meredith S Irwin and 9 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of pediatric surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Erin G BrownDivision of Pediatric Surgery, Department of Surgery, University of California Davis Children's Hospital, Sacramento, CA, USA. Electronic address: egbrown@ucdavis.edu.
E Stanton AdkinsDepartment of Pediatrics, University of South Carolina, Columbia, SC, USA.
Peter MatteiDivision of Pediatic Surgery, Department of Surgery, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Fredric A HofferDepartment of Radiology, University of Washington, Seattle, WA, USA.
Sandra L Wootton-GorgesDepartment of Radiology, University of California Davis Children's Hospital, Sacramento, CA, USA.
Wendy B LondonDepartment of Pediatrics, Dana-Farber Cancer Institute and Boston Children's Hospital, Boston, MA, USA.
Arlene NaranjoUniversity of Florida Children's Oncology Group Statistics and Data Center, Gainesville, FL, USA.
Mary L SchmidtDivision of Pediatric Hematology and Oncology, Department of Pediatrics, University of Illinois Cancer Center, Chicago, IL, USA.
Michael D HogartyDivision of Pediatric Hematology and Oncology, Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Meredith S IrwinDivision of Pediatric Hematology and Oncology, Department of Pediatrics, The Hospital for Sick Children, Toronto, ON, USA.
Susan L CohnDivision of Pediatric Hematology and Oncology, Department of Pediatrics, University of Chicago, Chicago, IL, USA.
Julie R ParkDivision of Pediatric Hematology and Oncology, Department of Pediatrics, St. Jude Children's Research Center, Memphis, TN, USA.
John M MarisDivision of Oncology, Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Rochelle BagatellDivision of Pediatric Hematology and Oncology, Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Clare J TwistDivision of Pediatric Hematology and Oncology, Department of Pediatrics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
Jed G NuchternDivision of Pediatric Surgery, Department of Surgery, Texas Children's Hospital, Houston, TX, USA.
Andrew M DavidoffDepartment of Surgery, St. Jude Children's Research Hospital, Memphis, TN, USA.
Erika A NewmanDivision of Pediatric Surgery, Department of Surgery, CS Mott Children's Hospital, Ann Arbor, MI, USA.
Dave R LalDivision of Pediatric Surgery, Department of Surgery, Children's Wisconsin, Milwaukee, WI, USA.

Funding

NCTN BIQSFP ANBL1531 (NRT)U10CA180886 · NCI · PUBLIC HEALTH INSTITUTE · PI Douglas S. Hawkins · 2014 to 2026
$390.6M
COG SDMC - Statistics CoreU10CA180899 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI TODD A ALONZO · 2014 to 2026
$132.8M
Discovering mechanisms of neuroblastoma tumorigenesis to improve patient outcomesR35CA220500 · NCI · CHILDREN'S HOSP OF PHILADELPHIA · PI JOHN M MARIS · 2017 to 2026
$8.7M
NCI NIH HHS R35 CA220500NCI NIH HHS U10 CA180886NCI NIH HHS U10 CA180899
6 · The paper itself

Abstract

backgroundThe International Neuroblastoma Risk Group (INRG) classifier utilizes a staging system based on pretreatment imaging criteria in which image-defined risk factors (IDRFs) are used to evaluate the extent of locoregional disease. Children's Oncology Group (COG) study ANBL0531 prospectively examined institutional determination of IDRF status and compared that to a standardized central review.

methodsBetween 9/2009-6/2011, patients with intermediate-risk neuroblastoma were enrolled on ANBL0531 and had IDRF assessment at treating institutions. Paired COG pediatric surgeons and radiologists performed blinded central review of diagnostic imaging for the presence or absence of IDRFs. Second blinded review was performed in cases of discordance. Comparison of local and central review was performed using the Kappa coefficient to determine concordance in IDRF assessment.

results211 patients enrolled in ANBL0531 underwent IDRF assessment; 3 patients were excluded due to poor image quality. Central reviewer pairs agreed on the presence or absence of any IDRF in 170/208 (81.7%; κ = 0.48) cases. Thirteen (6.3%) cases could not be adjudicated after second blinded review. Radiologists were more likely to identify IRDFs as present than surgeons (p < 0.001). Local and central reviewers agreed on the presence or absence of any IDRF in only108/208 (51.9%; κ = 0.06) cases.

conclusionsAmong experienced pediatric surgeons and radiologists participating in central review, concordance was moderate, with agreement in 81.7% of cases. On comparison of local and central assessment of IDRFs, concordance was poor. These data indicate that greater standardization, education, technology, and training are needed to improve the assessment of IDRFs in children with neuroblastoma. LEVEL OF EVIDENCE: Treatment Study, Level III.

Indexed as

NeuroblastomaChildChild, PreschoolFemaleHumansInfantMaleNeoplasm StagingProspective StudiesRisk AssessmentRisk FactorsConcordanceIDRFImage-defined risk factorNeuroblastoma

Identifiers

PMID39317567
PMCPMC11745918

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.